



PRIOR AUTHORIZATION POLICY

- POLICY:** Oncology (Oral – Epidermal Growth Factor Receptor Inhibitor)
Erlotinib Prior Authorization Policy
- Tarceva® (erlotinib tablets – Genentech, generic)

REVIEW DATE: 02/18/2026

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Erlotinib, a tyrosine kinase inhibitor, is indicated for the following uses:¹

- **Non-Small Cell Lung Cancer (NSCLC)**, treatment of patients whose tumors have epidermal growth factor receptor (*EGFR*) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
Limitations of use: The safety and efficacy of erlotinib have not been established in patients with NSCLC whose tumors have other *EGFR* mutations. Erlotinib is not recommended for use in combination with platinum-based chemotherapy.
- **Pancreatic Cancer**, in combination with gemcitabine as first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Guidelines

Erlotinib is addressed in the National Comprehensive Cancer Network (NCCN) guidelines.²⁻⁷

- **Bone Cancer:** Guidelines (version 2.2026 – December 19, 2025) note erlotinib (category 2A) as a treatment option under “Useful in Certain Circumstances” for patients with chordoma.³ The efficacy of erlotinib was demonstrated in patients with advanced chordoma resistant to imatinib.
- **Kidney Cancer:** Guidelines (version 1.2026 – July 24, 2025) no longer recommend erlotinib monotherapy as a treatment option for patients with recurrent or advanced renal cell carcinoma (RCC) of non-clear cell histology.⁶ The combination of bevacizumab with erlotinib is a treatment option (category 2A) for non-clear cell histology RCC in selected patients with advanced papillary RCC, including hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated RCC under “Other Recommended Regimens”.
- **Non-Small Cell Lung Cancer:** Guidelines (version 3.2026 – December 24, 2025) recommend erlotinib and other *EGFR* tyrosine kinase inhibitors as first-line treatment for patients with advanced or metastatic NSCLC with *EGFR* exon 19 deletions, exon 21 (L858R) substitution mutations (category 1 for both exon 19 and exon 21), L861Q, G719X, and S768I (category 2A for these three mutations).⁴ Erlotinib can be used in combination with bevacizumab or ramucirumab in this setting (category 2A both combinations).
- **Pancreatic Adenocarcinoma:** Guidelines (version 2.2025 – February 3, 2025) recommend the combination of gemcitabine and erlotinib as a first-line treatment option (category 1) for patients with metastatic disease under “Other Recommended Regimens”.⁵ The combination is also recommended for locally advanced first-line therapy (category 2A). In addition, the combination is recommended as a subsequent therapy option (category 2A) for locally advanced, metastatic, or recurrent disease under “Other Recommended Regimens”.
- **Vulvar Cancer:** Guidelines (version 2.2026 – January 6, 2026) recommend erlotinib (category 2B) as a second-line or subsequent treatment option for patients with advanced, recurrent, or metastatic vulvar cancer under “Other Recommended Regimens”.⁷

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of erlotinib. All approvals are provided for the duration noted below.

Tarceva® (erlotinib tablets - Genentech, generic) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

- 1. Non-Small Cell Lung Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient has advanced or metastatic disease; AND
 - C)** Patient has *EGFR* mutation-positive non-small cell lung cancer.
Note: Examples of *EGFR* mutation-positive non-small cell lung cancer include the following: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X, and S768I.
- 2. Pancreatic Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient has locally advanced, metastatic, or recurrent disease; AND
 - C)** The medication is used in combination with gemcitabine.

Other Uses with Supportive Evidence

- 3. Bone Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient has chordoma; AND
 - C)** Patient has tried at least one previous therapy.
- 4. Renal Cell Carcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient has Stage IV or relapsed renal cell carcinoma of non-clear cell histology; AND
 - C)** Patient meets BOTH of the following (i and ii):
 - i.** Patient has advanced papillary disease including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cell carcinoma; AND
 - ii.** The medication is used in combination with bevacizumab.
- 5. Vulvar Cancer.** Approve for 1 year if the patient meets BOTH of the following (A and B):
 - A)** Patient is \geq 18 years of age; AND
 - B)** Patient has advanced, recurrent, or metastatic disease.

CONDITIONS NOT COVERED

Tarceva® (erlotinib tablets - Genentech, generic) is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Renal Cell Carcinoma, Advanced – Clear Cell Histology.** NCCN Kidney Cancer guidelines (version 1.2026 – July 24, 2025) do not note erlotinib as a treatment option for advanced clear-cell renal cell carcinoma.⁶

REFERENCES

1. Tarceva® tablets [prescribing information]. South San Francisco, CA: Genentech; October 2016.
2. The NCCN Drugs & Biologics Compendium. © 2026 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2026. Search terms: erlotinib.
3. The NCCN Bone Cancer Clinical Practice Guidelines in Oncology (version 2.2026 – December 19, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2026.
4. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 3.2026 – December 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2026.
5. The NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology (version 2.2025 – February 3, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2026.
6. The NCCN Kidney Cancer Clinical Practice Guidelines in Oncology (version 1.2026 – July 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2026.
7. The NCCN Vulvar Cancer Clinical Practice Guidelines in Oncology (version 2.2026 – January 6, 2026). © 2026 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2026.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Non-Small Cell Lung Cancer: Deleted the word “sensitizing” while referring to <i>EGFR</i> mutations both in criteria and in the Note. Guidelines no longer use the word sensitizing to describe <i>EGFR</i> mutations.	02/07/2024
Annual Revision	Renal Cell Carcinoma: Changed disease qualifier description from “recurrent or advanced” to “Stage IV or relapsed” disease. Previously, for non-clear cell histology, erlotinib could be used as monotherapy for non-clear cell histology or in combination with bevacizumab for hereditary leiomyomatosis and renal cell carcinoma (HLRCC). Now, erlotinib monotherapy is no longer recommended in guidelines. So the “OR” separating the criteria describing Stage IV or relapsed disease and HLRCC was changed to an “AND”. In addition, for criterion referring to HLRCC, added “advanced papillary disease including HLRCC-associated renal cell carcinoma.” Breast Cancer: Deleted condition listed under “Conditions Not Covered”. Colon Cancer, Advanced: Deleted condition listed under “Conditions Not Covered”. Glioblastoma Multiforme (GBM): Deleted condition listed under “Conditions Not Covered”. Head and Neck Cancer: Deleted condition listed under “Conditions Not Covered”. Hepatocellular Carcinoma, Advanced: Deleted condition listed under “Conditions Not Covered”.	02/26/2025
Update	04/21/2025: The policy name was changed from “Oncology – Erlotinib PA Policy” to “Oncology (Oral – Epidermal Growth Factor Receptor Inhibitor) – Erlotinib PA Policy”.	N/A
Annual Revision	Non-Small Cell Lung Cancer: In reference to <i>EGFR</i> mutation-positive disease, the requirement that the mutation was detected by an approved test was removed.	02/18/2026

N/A – Not applicable.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.